Skip to Main content Skip to Navigation
Journal articles

Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013

Abstract : Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNFα) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFα drugs for HS. This article is protected by copyright. All rights reserved
Complete list of metadatas

Cited literature [15 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01207284
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, January 13, 2016 - 12:40:52 PM
Last modification on : Wednesday, October 14, 2020 - 3:45:34 AM
Long-term archiving on: : Friday, November 11, 2016 - 4:30:24 AM

File

Anti-TNFα therapy for hidrade...
Files produced by the author(s)

Identifiers

Citation

E. Sbidian, C. Hotz, J. Seneschal, A. Maruani, F. Amelot, et al.. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. British Journal of Dermatology, Wiley, 2016, 174 (3), pp.667-670. ⟨10.1111/bjd.14199⟩. ⟨hal-01207284⟩

Share

Metrics

Record views

813

Files downloads

1052